Fast vaccine design and development based on correlates of protection (COPs): Influenza as a trendsetter

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 7, 2014, Pages 1935-1948

  Van Els, Cécile ^a   Mjaaland, Siri ^b   Næss, Lisbeth ^b   Sarkadi, Julia ^c   Gonczol, Eva ^c   Korsholm, Karen Smith ^d   Hansen, Jon ^d   De Jonge, Jørgen ^a   Kersten, Gideon ^e,f   Warner, Jennifer ^g   Semper, Amanda ^g   Kruiswijk, Corine ^e   Oftung, Fredrik ^b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^d STATENS SERUM INSTITUT   (Denmark)

^e Institute for Translational Vaccinology   (Netherlands)

^f LEIDEN UNIVERSITY   (Netherlands)

^g PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

COP based vaccine design; Correlates of protection; Influenza; Vaccine development

Indexed keywords

INFLUENZA VACCINE; NEW DRUG; VIRUS ANTIGEN; BACTERIAL VACCINE; BIOLOGICAL MARKER; VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; CELLULAR IMMUNITY; CONCEPTUAL FRAMEWORK; CORRELATES OF PROTECTION; CROSS REACTION; DRUG DESIGN; DRUG EFFICACY; DRUG LEGISLATION; DRUG RESEARCH; DRUG SCREENING; DRUG USE; HUMAN; IMMUNE RESPONSE; INFLUENZA VIRUS A; INFLUENZA VIRUS B; KNOWLEDGE; MUCOSAL IMMUNITY; NONHUMAN; PANDEMIC INFLUENZA; PRIMARY PREVENTION; REVIEW; SEASONAL INFLUENZA; VACCINE PRODUCTION; VIRUS ENVELOPE; DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; TIME FACTOR;

BACTERIAL VACCINES; BIOMARKERS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; TIME FACTORS; VIRAL VACCINES;

EID: 84908374941     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28639     Document Type: Review

References (148)

1. Gage KL, Burkot TR, Eisen RJ, Hayes EB. Climate and vectorborne diseases. Am J Prev Med 2008; 35:436-50; PMID:18929970; http://dx.doi.org/10.1016/j.amepre.2008.08.030
2. Semenza JC, Menne B. Climate change and infectious diseases in Europe. Lancet Infect Dis 2009; 9:365-75; PMID:19467476; http://dx.doi.org/10.1016/S1473-3099(09)70104-5
3. WHO. Severe acute respiratory syndrome (SARS): Status of the outbreak and lessons for the immediate future. 2003. Available from: http://www.who.int/csr/don/2003-04-11/en/
4. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, et al.; KSA MERS-CoV Investigation Team. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369:407-16; PMID:23782161; http://dx.doi.org/10.1056/NEJMoa1306742
5. WHO. Evolution of a pandemic A(H1N1) 2009. 2013.
6. Xiong X, Martin SR, Haire LF, Wharton SA, Daniels RS, Bennett MS, McCauley JW, Collins PJ, Walker PA, Skehel JJ, et al. Receptor binding by an H7N9 influenza virus from humans. Nature 2013; 499:496-9; PMID:23787694; http://dx.doi.org/10.1038/nature12372
7. WHO. Table of Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2013. 2013. Available from: http://www.who.int/inf luenza/human-animal-interface/EN-GIP-20131008CumulativeNumberH5N1cases.pdf
8. Ambrose CS, Wu X, Belshe RB. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J 2010; 29:806-11; PMID:20458256; http://dx.doi.org/10.1097/INF.0b013e3181e2872f
9. Ansaldi F, Orsi A, de Florentiis D, Parodi V, Rappazzo E, Coppelli M, Durando P, Icardi G. Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: Evaluation of immunogenicity, cross-protection, safety and tolerability. Hum Vaccin Immunother 2013; 9: In press; PMID:23295262; http://dx.doi.org/10.4161/hv.23240.
10. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011; 365:1406-16; PMID:21995388; http://dx.doi.org/10.1056/NEJMoa1010331
11. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29:7733-9; PMID:21835220; http://dx.doi.org/10.1016/j.vaccine.2011.07.128
12. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70:767-77; PMID:4509641; http://dx.doi.org/10.1017/S0022172400022610
13. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003; 115:63-73; PMID:15088777
14. Treanor J, Wright PF. Immune correlates of protection against influenza in the human challenge model. Dev Biol (Basel) 2003; 115:97-104; PMID:15088780
15. Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986; 24:157-60; PMID:3722363
16. Stephenson I, Wood JM, Nicholson KG, Zambon MC. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol 2003; 70:391-8; PMID:12767002; http://dx.doi.org/10.1002/jmv.10408
17. Monto AS, Maassab HF. Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test. J Clin Microbiol 1981; 13:54-7; PMID:7462419
18. Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011; 30:1081-5; PMID:21983214; http://dx.doi.org/10.1097/INF.0b013e3182367662
19. Granström M, Voordouw AC. Registration of influenza vaccines for children in Europe. Vaccine 2011; 29:7572-5; PMID:21820474; http://dx.doi.org/10.1016/j.vaccine.2011.08.017
20. Eichelberger M, Golding H, Hess M, Weir J, Subbarao K, Luke CJ, Friede M, Wood D. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine 2008; 26:4299-303; PMID:18582523; http://dx.doi.org/10.1016/j.vaccine.2008.06.012
21. Haaheim LR, Katz JM. Immune correlates of protection against influenza: challenges for licensure of seasonal and pandemic influenza vaccines, Miami, FL, USA, March 1-3, 2010. Influenza Other Respir Viruses 2011; 5:288-95; PMID:21651740; http://dx.doi.org/10.1111/j.1750-2659.2011.00242.x
22. Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, Rappaport R, Eldridge JH, Gruber WC. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008; 15:1042-53; PMID:18448618; http://dx.doi.org/10.1128/CVI.00397-07
23. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC. T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006;176(10):6333-9
24. McElhaney JE. Influenza vaccine responses in older adults. Ageing Res Rev 2011; 10:379-88; PMID:21055484; http://dx.doi.org/10.1016/j.arr.2010.10.008
25. Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus Res 2011; 162:19-30; PMID:21963677; http://dx.doi.org/10.1016/j.virusres.2011.09.022
26. McCullers JA, Huber VC. Correlates of vaccine protection from influenza and its complications. Hum Vaccin Immunother 2012; 8:34-44; PMID:22252001; http://dx.doi.org/10.4161/hv.8.1.18214
27. Dormitzer PR, Tsai TF, Del Giudice G. New technologies for influenza vaccines. Hum Vaccin Immunother 2012; 8:45-58; PMID:22251994; http://dx.doi.org/10.4161/hv.8.1.18859
28. Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med 2010; 363:2036-44; PMID:21083388; http://dx.doi.org/10.1056/NEJMra1002842
29. Shaw A. New technologies for new influenza vaccines. Vaccine 2012; 30:4927-33; PMID:22579861; http://dx.doi.org/10.1016/j.vaccine.2012.04.095
30. WHO. Table for pandemic and potentially pandemic influenza vaccines. 2013. Available from: http://www.who.int/entity/immunization/research/development/Table-pandemic-vaccines.xls?ua=1
31. Amorij JP, Hinrichs WLj, Frijlink HW, Wilschut JC, Huckriede A. Needle-free influenza vaccination. Lancet Infect Dis 2010; 10:699-711; PMID:20883966; http://dx.doi.org/10.1016/S1473-3099(10)70157-2
32. Palese P. Making better influenza virus vaccines? Emerg Infect Dis 2006; 12:61-5; PMID:16494719; http://dx.doi.org/10.3201/eid1201.051043
33. Monto AS, Ohmit SE. Seasonal influenza vaccines: evolutions and future trends. Expert Rev Vaccines 2009; 8:383-9; PMID:19348555; http://dx.doi.org/10.1586/erv.09.9
34. Gilbert SC. Advances in the development of universal influenza vaccines. Influenza Other Respi Viruses 2013;7(5):750-8 PMID:22998622; http://dx.doi.org/10.1111/irv.12013
35. Rudolph W, Ben Yedidia T. A universal influenza vaccine: where are we in the pursuit of this "Holy Grail"? Hum Vaccin 2011; 7:10-1; PMID:21285533; http://dx.doi.org/10.4161/hv.7.1.14925
36. Safdar A, Cox MM. Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use. Expert Opin Investig Drugs 2007; 16:927-34; PMID:17594180; http://dx.doi.org/10.1517/13543784.16.7.927
37. Hillaire ML, Osterhaus AD, Rimmelzwaan GF. Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol. 2011;2011:939860
38. Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009; 8:499-508; PMID:19348565; http://dx.doi.org/10.1586/erv.09.6
39. The First WHO integrated meeting on development and clinical trials of Influenza vaccines that induce broadly protective and long-lasting immune responses. 2013. Available from: http://www.who.int/immunization/research/meetings-workshops/fluvaccines-devclinicaltrials-jan13/en/
40. Van Kerkhove MD, Broberg E, Engelhardt OG, Wood J, Nicoll A; CONSISE steering committee. The consortium for the standardization of influenza seroepidemiology (CONSISE): a global partnership to standardize influenza seroepidemiology and develop influenza investigation protocols to inform public health policy. Influenza Other Respir Viruses 2013; 7:231-4; PMID:23280042; http://dx.doi.org/10.1111/irv.12068
41. Wagner R, Pfleiderer M. Reproducibility of assays for influenza vaccine immunogenicity determination: progress towards consistency. Expert Rev Vaccines 2012; 11:881-3; PMID:23002967; http://dx.doi.org/10.1586/erv.12.62
42. Reber A, Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines 2013; 12:519-36; PMID:23659300; http://dx.doi.org/10.1586/erv.13.35
43. Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of influenza vaccines. Vaccine 2008; 26(Suppl 4):D41-4; PMID:19230158; http://dx.doi.org/10.1016/j.vaccine.2008.07.043
44. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47(3):401-9
45. Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181:1133-7; PMID:10720541; http://dx.doi.org/10.1086/315323
46. Laidlaw BJ, Decman V, Ali MA, Abt MC, Wolf AI, Monticelli LA, Mozdzanowska K, Angelosanto JM, Artis D, Erikson J, et al. Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity. PLoS Pathog 2013; 9:e1003207; PMID:23516357; http://dx.doi.org/10.1371/journal.ppat.1003207
47. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246-51; PMID:19251591; http://dx.doi.org/10.1126/science.1171491
48. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008; 3:e3942; PMID:19079604; http://dx.doi.org/10.1371/journal.pone.0003942
49. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265-73; PMID:19234466; http://dx.doi.org/10.1038/nsmb.1566
50. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, et al. Highly conserved protective epitopes on influenza B viruses. Science 2012; 337:1343-8; PMID:22878502; http://dx.doi.org/10.1126/science.1222908
51. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Pearce MB, Yassine HM, Boyington JC, et al.; VRC 306 Study Team. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11:916-24; PMID:21975270; http://dx.doi.org/10.1016/S1473-3099(11)70240-7
52. Bommakanti G, Lu X, Citron MP, Najar TA, Heidecker GJ, ter Meulen J, Varadarajan R, Liang X. Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J Virol 2012; 86:13434-44; PMID:23015722; http://dx.doi.org/10.1128/JVI.01429-12
53. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, García-Sastre A, Palese P. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010; 1:1; PMID:20689752; http://dx.doi.org/10.1128/mBio.00018-10
54. Krammer F, Pica N, Hai R, Margine I, Palese P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 2013; 87:6542-50; PMID:23576508; http://dx.doi.org/10.1128/JVI.00641-13
55. Corti D, Suguitan AL Jr., Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010; 120:1663-73; PMID:20389023; http://dx.doi.org/10.1172/JCI41902
56. Murphy BR, Kasel JA, Chanock RM. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 1972; 286:1329-32; PMID:5027388; http://dx.doi.org/10.1056/NEJM197206222862502
57. Couch RB, Atmar RL, Keitel WA, Quarles JM, Wells J, Arden N, Niño D. Randomized comparative study of the serum antihemagglutinin and anti-neuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine 2012; 31:190-5; PMID:23107591; http://dx.doi.org/10.1016/j.vaccine.2012.10.065
58. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4:e59; PMID:17298168; http://dx.doi.org/10.1371/journal.pmed.0040059
59. Monto AS, Kendal AP. Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1973; 1(7804):623-5; PMID:4121842; http://dx.doi.org/10.1016/S0140-6736(73)92196-X
60. Pushko P, Kort T, Nathan M, Pearce MB, Smith G, Tumpey TM. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 2010; 28:4771-6; PMID:20470801; http://dx.doi.org/10.1016/j.vaccine.2010.04.093
61. Couch RB, Atmar RL, Franco LM, Quarles JM, Wells J, Arden N, Niño D, Belmont JW. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 2013; 207:974-81; PMID:23307936; http://dx.doi.org/10.1093/infdis/jis935
62. Lambré CR, Terzidis H, Greffard A, Webster RG. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J Immunol Methods 1990; 135:49-57; PMID:1703190; http://dx.doi.org/10.1016/0022-1759(90)90255-T
63. Cate TR, Rayford Y, Niño D, Winokur P, Brady R, Belshe R, Chen W, Atmar RL, Couch RB. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010; 28:2076-9; PMID:20044052; http://dx.doi.org/10.1016/j.vaccine.2009.12.041
64. Gravel C, Li C, Wang J, Hashem AM, Jaentschke B, Xu KW, Lorbetskie B, Gingras G, Aubin Y, Van Domselaar G, et al. Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Vaccine 2010; 28:5774-84; PMID:20621113; http://dx.doi.org/10.1016/j.vaccine.2010.06.075
65. European Medicines Agency. Scientific workshop on serology assays and correlates of protection for influenza vaccines. 2010. Available from: http://www.ema.europa.eu/docs /en-GB/document-library/Report/2010/12/WC500100205.pdf
66. Gavrilov V, Orekov T, Alabanza C, Porika U, Jiang H, Connolly K, Pincus S. Influenza virus-like particles as a new tool for vaccine immunogenicity testing: validation of a neuraminidase neutralizing antibody assay. J Virol Methods 2011; 173:364-73; PMID:21419169; http://dx.doi.org/10.1016/j.jviromet.2011.03.011
67. Hassantoufighi A, Zhang H, Sandbulte M, Gao J, Manischewitz J, King L, Golding H, Straight TM, Eichelberger MC. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. Vaccine 2010; 28:790-7; PMID:19887135; http://dx.doi.org/10.1016/j.vaccine.2009.10.066
68. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, Van Rooijen N, Verbeek S, Fiers W, Saelens X. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol. 2011;186(2):1022-31
69. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol. 2004;172(9):5598-605
70. Shaw AR. Universal influenza vaccine: the holy grail? Expert Rev Vaccines 2012; 11:923-7; PMID:23002973; http://dx.doi.org/10.1586/erv.12.73
71. Fu TM, Grimm KM, Citron MP, Freed DC, Fan J, Keller PM, Shiver JW, Liang X, Joyce JG. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009; 27:1440-7; PMID:19146898; http://dx.doi.org/10.1016/j.vaccine.2008.12.034
72. Livingston BD, Higgins D, Van Nest G. Evolving strategies for the prevention of influenza infection: potential for multistrain targeting. BioDrugs. 2006;20(6):335-40
73. Zhong W, He J, Tang X, Liu F, Lu X, Zeng H, Vafai A, Fu TM, Katz JM, Hancock K. Development and evaluation of an M2-293FT cell-based flow cytometric assay for quantification of antibody response to native form of matrix protein 2 of influenza A viruses. J Immunol Methods 2011; 369:115-24; PMID:21570401; http://dx.doi.org/10.1016/j.jim.2011.04.010
74. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309:13-7; PMID:6602294; http://dx.doi.org/10.1056/NEJM198307073090103
75. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, Salimi N, Vita R, Ponomarenko J, Scheuermann RH, Sette A, et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 2009; 106:20365-70; PMID:19918065; http://dx.doi.org/10.1073/pnas.0911580106
76. McElhaney JE, Gravenstein S, Upshaw CM, Hooton JW, Krause P, Drinka P, Bleackley RC. Granzyme B: a marker of risk for influenza in institutionalized older adults. Vaccine 2001; 19:3744-51; PMID:11395209; http://dx.doi.org/10.1016/S0264-410X(01)00087-1
77. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 2013; 19:1305-12; PMID:24056771; http://dx.doi.org/10.1038/nm.3350
78. McElhaney JE. Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response. Expert Rev Vaccines 2009; 8:593-606; PMID:19397416; http://dx.doi.org/10.1586/erv.09.12
79. McElhaney JE, Ewen C, Zhou X, Kane KP, Xie D, Hager WD, Barry MB, Kleppinger A, Wang Y, Bleackley RC. Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 2009; 27:2418-25; PMID:19368783; http://dx.doi.org/10.1016/j.vaccine.2009.01.136
80. Shahid Z, Kleppinger A, Gentleman B, Falsey AR, McElhaney JE. Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine 2010; 28:6145-51; PMID:20646987; http://dx.doi.org/10.1016/j.vaccine.2010.07.036
81. Bentebibel SE, Lopez S, Obermoser G, Schmitt N, Mueller C, Harrod C, Flano E, Mejias A, Albrecht RA, Blankenship D, et al. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med. 2013;5(176):176ra32
82. Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4+ T cells in immunity to viruses. Nat Rev Immunol 2012; 12:136-48; PMID:22266691
83. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012; 18:274-80; PMID:22286307; http://dx.doi.org/10.1038/nm.2612
84. Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert AK, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A 2009; 106:3877-82; PMID:19237568; http://dx.doi.org/10.1073/pnas.0813390106
85. Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respir Viruses 2011; 5:426-37; PMID:21668670; http://dx.doi.org/10.1111/j.1750-2659.2011.00256.x
86. Kang KS, Lee N, Shin MS, Kim SD, Yu Y, Mohanty S, Belshe RB, Montgomery RR, Shaw AC, Kang I. An altered relationship of influenza vaccine-specific IgG responses with T cell immunity occurs with aging in humans. Clin Immunol 2013; 147:79-88; PMID:23578549; http://dx.doi.org/10.1016/j.clim.2013.02.022
87. Hillaire ML, van Trierum SE, Kreijtz JH, Bodewes R, Geelhoed-Mieras MM, Nieuwkoop NJ, Fouchier RA, Kuiken T, Osterhaus AD, Rimmelzwaan GF. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J Gen Virol 2011; 92:2339-49; PMID:21653752; http://dx.doi.org/10.1099/vir.0.033076-0
88. Hillaire M, Rimmelzwaan G, Kreijtz J. Clearance of influenza virus infections by T cells: risk of collateral damage? Curr Opin Virol. 2013;3(4):430-7
89. Sun J, Braciale TJ. Role of T cell immunity in recovery from influenza virus infection. Curr Opin Virol. 2013;3(4):425-9
90. Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, Henningson J, Vincent AL, Golding H. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med. 2013;5(200):200ra114
91. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis. 2011;52(1):1-7
92. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis. 2012;55(1):19-25
93. Pleguezuelos O, Robinson S, Stoloff GA, Caparrós-Wanderley W. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial. Vaccine 2012; 30:4655-60; PMID:22575166; http://dx.doi.org/10.1016/j.vaccine.2012.04.089
94. Systems IT. Flunisyn, pan-influenza strain vaccine. Trends Immunol. 2011;32(11):524-31
95. Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T, Ervin JE, Greenberg RN, Strout C, Treanor JJ, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013; 13:238-50; PMID:23369412; http://dx.doi.org/10.1016/S1473-3099(12)70345-6
96. Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T, Gilbert SC. Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens. Mol Ther. 2014;22(3):668-74
97. Gijzen K, Liu WM, Visontai I, Oftung F, van der Werf S, Korsvold GE, Pronk I, Aaberge IS, Tütto A, Jankovics I, et al. Standardization and validation of assays determining cellular immune responses against influenza. Vaccine 2010; 28:3416-22; PMID:20206285; http://dx.doi.org/10.1016/j.vaccine.2010.02.076
98. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006; 12:48-54; PMID:16494717; http://dx.doi.org/10.3201/eid1201.051237
99. Rose MA, Zielen S, Baumann U. Mucosal immunity and nasal influenza vaccination. Expert Rev Vaccines 2012; 11:595-607; PMID:22827245; http://dx.doi.org/10.1586/erv.12.31
100. Asahi Y, Yoshikawa T, Watanabe I, Iwasaki T, Hasegawa H, Sato Y, Shimada S, Nanno M, Matsuoka Y, Ohwaki M, et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol. 2002;168(6):2930-8
101. Taylor HP, Dimmock NJ. Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. J Exp Med 1985; 161:198-209; PMID:2981953; http://dx.doi.org/10.1084/jem.161.1.198
102. Mazanec MB, Coudret CL, Fletcher DR. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol 1995; 69:1339-43; PMID:7815518
103. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-96; PMID:17301299; http://dx.doi.org/10.1056/NEJMoa065368
104. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36-44; PMID:22032844; http://dx.doi.org/10.1016/S1473-3099(11)70295-X
105. Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, Wittes J. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Vaccine 2009; 27:1101-10; PMID:19095024; http://dx.doi.org/10.1016/j.vaccine.2008.11.093
106. Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, Abate G, Sakala IG, Edwards KM, Creech CB, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011; 204:845-53; PMID:21846636; http://dx.doi.org/10.1093/infdis/jir436
107. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007; 25:5467-84; PMID:17227687; http://dx.doi.org/10.1016/j.vaccine.2006.12.001
108. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6:148-58; PMID:16491139; http://dx.doi.org/10.1038/nri1777
109. Weiner HL. The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells. Nat Immunol 2001; 2:671-2; PMID:11477400; http://dx.doi.org/10.1038/90604
110. Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, Bachmann MF. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 2008; 38:114-26; PMID:18081037; http://dx.doi.org/10.1002/eji.200636959
111. Burt D, Mallett C, Plante M, Zimmermann J, Torossian K, Fries L. Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations. Expert Rev Vaccines 2011; 10:365-75; PMID:21434804; http://dx.doi.org/10.1586/erv.10.172
112. Saluja V, Amorij JP, van Roosmalen ML, Leenhouts K, Huckriede A, Hinrichs WL, Frijlink HW. Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. AAPS J 2010; 12:109-16; PMID:20058113; http://dx.doi.org/10.1208/s12248-009-9168-2
113. Zhang J. Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines. Viruses 2012; 4:2711-35; PMID:23202501; http://dx.doi.org/10.3390/v4112711
114. Peters W, Brandl JR, Lindbloom JD, Martinez CJ, Scallan CD, Trager GR, Tingley DW, Kabongo ML, Tucker SN. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans. Vaccine 2013; 31:1752-8; PMID:23357198; http://dx.doi.org/10.1016/j.vaccine.2013.01.023
115. Park HJ, Ferko B, Byun YH, Song JH, Han GY, Roethl E, Egorov A, Muster T, Seong B, Kweon MN, et al. Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice. PLoS One 2012; 7:e39921; PMID:22761928; http://dx.doi.org/10.1371/journal.pone.0039921
116. Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, Cheon IS, Joo DH, Cho CH, Song MS, et al. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. PLoS One 2011; 6:e27953; PMID:22140491; http://dx.doi.org/10.1371/journal.pone.0027953
117. Song JH, Nguyen HH, Cuburu N, Horimoto T, Ko SY, Park SH, Czerkinsky C, Kweon MN. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci U S A 2008; 105:1644-9; PMID:18227512; http://dx.doi.org/10.1073/pnas.0708684105
118. Shen X, Söderholm J, Lin F, Kobinger G, Bello A, Gregg DA, Broderick KE, Sardesai NY. Influenza A vaccines using linear expression cassettes delivered via electroporation afford full protection against challenge in a mouse model. Vaccine 2012; 30:6946-54; PMID:22406460; http://dx.doi.org/10.1016/j.vaccine.2012.02.071
119. Barría MI, Garrido JL, Stein C, Scher E, Ge Y, Engel SM, Kraus TA, Banach D, Moran TM. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis 2013; 207:115-24; PMID:23087433; http://dx.doi.org/10.1093/infdis/jis641
120. Ainai A, Tamura S, Suzuki T, van Riet E, Ito R, Odagiri T, Tashiro M, Kurata T, Hasegawa H. Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults. Hum Vaccin Immunother 2013; 9:1962-70; PMID:23896606; http://dx.doi.org/10.4161/hv.25458
121. Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining WN, Means AR, Kasturi SP, Khan N, Li GM, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011; 12:786-95; PMID:21743478; http://dx.doi.org/10.1038/ni.2067
122. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009; 10:116-25; PMID:19029902; http://dx.doi.org/10.1038/ni.1688
123. Lambert ND, Ovsyannikova IG, Pankratz VS, Jacobson RM, Poland GA. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Rev Vaccines 2012; 11:985-94; PMID:23002979; http://dx.doi.org/10.1586/erv.12.61
124. Obermoser G, Presnell S, Domico K, Xu H, Wang Y, Anguiano E, Thompson-Snipes L, Ranganathan R, Zeitner B, Bjork A, et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 2013; 38:831-44; PMID:23601689; http://dx.doi.org/10.1016/j.immuni.2012.12.008
125. Bodewes R, Rimmelzwaan GF, Osterhaus AD. Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev Vaccines 2010; 9:59-72; PMID:20021306; http://dx.doi.org/10.1586/erv.09.148
126. Belser JA, Tumpey TM. H5N1 pathogenesis studies in mammalian models. Virus Res 2013; 178:168-85; PMID:23458998; http://dx.doi.org/10.1016/j.virusres.2013.02.003
127. Tripp RA, Tompkins SM. Animal models for evaluation of influenza vaccines. Curr Top Microbiol Immunol 2009; 333:397-412; PMID:19768416; http://dx.doi.org/10.1007/978-3-540-92165-3-19
128. van der Laan JW, Herberts C, Lambkin-Williams R, Boyers A, Mann AJ, Oxford J. Animal models in influenza vaccine testing. Expert Rev Vaccines 2008; 7:783-93; PMID:18665776; http://dx.doi.org/10.1586/14760584.7.6.783
129. Bodewes R, Kreijtz JH, van Amerongen G, Fouchier RA, Osterhaus AD, Rimmelzwaan GF, Kuiken T. Pathogenesis of Influenza A/H5N1 virus infection in ferrets differs between intranasal and intratracheal routes of inoculation. Am J Pathol 2011; 179:30-6; PMID:21640972; http://dx.doi.org/10.1016/j.ajpath.2011.03.026
130. Marois I, Cloutier A, Garneau É, Richter MV. Initial infectious dose dictates the innate, adaptive, and memory responses to influenza in the respiratory tract. J Leukoc Biol 2012; 92:107-21; PMID:22504848
131. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, Naghdaliyev A, Peiris JS, Shindo N, Soeroso S, et al.; Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261-73; PMID:18199865; http://dx.doi.org/10.1056/NEJMra0707279
132. Korteweg C, Gu J. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am J Pathol 2008; 172:1155-70; PMID:18403604; http://dx.doi.org/10.2353/ajpath.2008.070791
133. Plotnicky H, Cyblat-Chanal D, Aubry JP, Derouet F, Klinguer-Hamour C, Beck A, Bonnefoy JY, Corvaïa N. The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice. Virology 2003; 309:320-9; PMID:12758178; http://dx.doi.org/10.1016/S0042-6822(03)00072-2
134. Tan AC, Deliyannis G, Bharadwaj M, Brown LE, Zeng W, Jackson DC. The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus. Immunol Cell Biol 2013; 91:96-104; PMID:23146941; http://dx.doi.org/10.1038/icb.2012.54
135. Martel CJ, Aasted B. Characterization of antibodies against ferret immunoglobulins, cytokines and CD markers. Vet Immunol Immunopathol 2009; 132:109-15; PMID:19505731; http://dx.doi.org/10.1016/j.vetimm.2009.05.011
136. Rutigliano JA, Doherty PC, Franks J, Morris MY, Reynolds C, Thomas PG. Screening monoclonal antibodies for cross-reactivity in the ferret model of influenza infection. J Immunol Methods 2008; 336:71-7; PMID:18485358; http://dx.doi.org/10.1016/j.jim.2008.04.003
137. Ochi A, Danesh A, Seneviratne C, Banner D, Devries ME, Rowe T, Xu L, Ran L, Czub M, Bosinger SE, et al. Cloning, expression and immunoassay detection of ferret IFN-gamma. Dev Comp Immunol 2008; 32:890-7; PMID:18262264; http://dx.doi.org/10.1016/j.dci.2007.12.008
138. Pillet S, Kobasa D, Meunier I, Gray M, Laddy D, Weiner DB, von Messling V, Kobinger GP. Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets. Vaccine 2011; 29:6793-801; PMID:21211587; http://dx.doi.org/10.1016/j.vaccine.2010.12.059
139. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247-58; PMID:18323851; http://dx.doi.org/10.1038/nri2274
140. Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, Ben-Yedidia T. Safety and immunogenicity of multimeric-001 - a novel universal influenza vaccine. J Clin Immunol 2012; 32:595-603; PMID:22318394; http://dx.doi.org/10.1007/s10875-011-9632-5
141. Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, Dunne CE, Chaplin JA, Rusalov D, Rolland AP, Fisher CL, et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010; 28:2565-72; PMID:20117262; http://dx.doi.org/10.1016/j.vaccine.2010.01.029
142. Jones S, Evans K, McElwaine-Johnn H, Sharpe M, Oxford J, Lambkin-Williams R, Mant T, Nolan A, Zambon M, Ellis J, et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 2009; 27:2506-12; PMID:19368793; http://dx.doi.org/10.1016/j.vaccine.2009.02.061
143. Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G, Vézina LP. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010; 5:e15559; PMID:21203523; http://dx.doi.org/10.1371/journal.pone.0015559
144. Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012; 206:158-66; PMID:22551811; http://dx.doi.org/10.1093/infdis/jis330
145. Hubby B, Talarico T, Maughan M, Reap EA, Berglund P, Kamrud KI, Copp L, Lewis W, Cecil C, Norberg P, et al. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 2007; 25:8180-9; PMID:17961878; http://dx.doi.org/10.1016/j.vaccine.2007.09.038
146. Taylor DN, Treanor JJ, Sheldon EA, Johnson C, Umlauf S, Song L, Kavita U, Liu G, Tussey L, Ozer K, et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 2012; 30:5761-9; PMID:22796139; http://dx.doi.org/10.1016/j.vaccine.2012.06.086
147. Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, Ozer K, Tussey L, Shaw A. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 2011; 29:4897-902; PMID:21596084; http://dx.doi.org/10.1016/j.vaccine.2011.05.001
148. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011; 29:5145-52; PMID:21624416; http://dx.doi.org/10.1016/j.vaccine.2011.05.041